City Therapeutics IPO: revenue, losses and offering terms from its S-1
City Therapeutics priced its IPO at $18 a share on 16 Oct 2026 and raised $200 million. Its shares trade on Nasdaq as CTY. Revenue was $13.6 million in 2025, up 4.9 times from 2024, with a net loss of $58.5 million.
Headlines
- Revenue, 2025
- $14M
- Up 4.9 times on the year before
- Net loss, 2025
- $59M
- Revenue, First half of 2026
- $6M
- Up 14% on a year earlier
- IPO price
- $18
- $200M raised
City Therapeutics IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Global Market
- Ticker
- CTY
- IPO price
- $18
- Shares offered
- 11,111,111
- Raised
- $200M
- Registered
- $212M, the amount the filing fee is paid on
- Underwriters
- Goldman Sachs & Co. LLC, Jefferies, Stifel and Oppenheimer & Co.
- First filed
- 24 Sep 2026
City Therapeutics revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2024 | $3M | - | -$28M |
| 2025 | $14M | -$60M | -$59M |
| First half of 2025 | $6M | - | - |
| First half of 2026 | $6M | -$51M | -$53M |
City Therapeutics share structure and company facts
- Employees
- 81
- Headquarters
- Cambridge, Massachusetts
City Therapeutics shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $18
- Priced 16 Oct 2026
- First close
- $22.40
- +24% on the IPO price
- Latest close
- $20.79
- +16% on the IPO price
City Therapeutics' IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from City Therapeutics' newest prospectus (424B4 filed 16 Oct 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.